DISCOVER
Managed Access Programmes
Our technological innovation platform called “CleanWeb-MAP” (CleanWeb Managed Access Programme) facilitates access to new drugs by eligible patients.
There are multiple terms that fall under the umbrella of MAP, including Compassionate Use, Early Access, Named Patient Use and Individual Patient Request Programmes to name but a few. The terms used may vary from country to country depending on local laws and regulations. Our module is closely linked to our CleanWeb software platform for medical data collection, it enables self-registration of prescribing physicians and pharmacists, for each new product related to MAP.
Ethical and compliant
mechanism of access to drugs
• MAPs provide alternative treatments to patients with life-threatening diseases with no therapeutic options
• CleanWeb-MAP meets local laws and regulations Seamless Managed Access Programmes
Entrust your project
to our expert
data management team
Drug use outcome
in a real-world setting
Allows you to gain valuable early experience with a product
CleanWeb-MAP facilitates the management of MAPs in real-life conditions
CleanWeb-MAP:
streamlined interactions with stakeholders
Each role and access are clearly defined Physicians, Nurses, Medical Advisor, Programme Manager, Pharmacovigilance officer, Logistics perfectly interact in the MAP cycle process.
The ordering process and the availability of drugs are assured in interaction with any external system and data source.
CleanWeb-MAP allows for the involvement of other stakeholders and for the integration of many additional behaviours (e.g., Pharmacist).
Do you want to learn more about our e-health solution? Just fill in the form and we will get back to you shortly
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
April 29, 2025
May 5 & 6 – Basel Telemedicine Technologies is pleased to present its CleanWeb™ eClinical suite, offering flexible, regulatory-compliant solutions tailored to every phase of clinical trials. Our platform includes a wide range of modules, such as eCRF, Randomization & Trial Supply Management, ePRO, eTMF, eConsent, Data Visualization, Vigilance, Imaging, CTMS, and more. We invite […]
April 29, 2025
Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]
April 29, 2025
Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]